Hormone Disorder Treatment

Octreotide (SANDOSTATIN LAR) 10MG 30 Tablet

$2,783.00

SANDOSTATIN LAR Tablet offers a valuable treatment option for patients with acromegaly and certain neuroendocrine tumors, providing effective symptom control and tumor management with a convenient long-acting formulation.

Quantity

Octreotide (SANDOSTATIN LAR) 10MG 30 Tablet quantity

Add to cart

Tag:

Octreotide (SANDOSTATIN LAR)

Description

SANDOSTATIN LAR Tablet contains Octreotide in a strength of 10mg, serving as a medication primarily prescribed for the treatment of acromegaly, a hormonal disorder characterized by excessive growth hormone production, as well as for the management of certain neuroendocrine tumors.

Key Features:

• Acromegaly Treatment: SANDOSTATIN LAR Tablet is indicated for the long-term treatment of acromegaly, a hormonal disorder characterized by excessive growth hormone secretion, typically caused by a pituitary adenoma.
• Octreotide Mechanism of Action: Octreotide, the active ingredient in SANDOSTATIN LAR, is a synthetic analog of somatostatin, a hormone that inhibits the release of growth hormone and other hormones such as insulin and glucagon. By mimicking somatostatin’s actions, Octreotide helps regulate hormone secretion and control tumor growth.
• Neuroendocrine Tumor Management: SANDOSTATIN LAR may also be used for the management of certain neuroendocrine tumors, including carcinoid tumors, vasoactive intestinal peptide-secreting tumors (VIPomas), and pancreatic neuroendocrine tumors (pNETs).
• Long-Acting Formulation: SANDOSTATIN LAR is formulated as a long-acting release (LAR) formulation, allowing for extended drug release and prolonged duration of action, which reduces the frequency of injections required compared to short-acting formulations.
• Fixed-Dose Tablet: SANDOSTATIN LAR Tablet contains a fixed dose of Octreotide (10mg) in each tablet, simplifying dosing and ensuring consistent medication delivery.
• Subcutaneous Administration: Administered via subcutaneous injection, usually once every 4 weeks, SANDOSTATIN LAR offers convenient dosing for patients with acromegaly and neuroendocrine tumors, minimizing treatment burden.
• Clinical Efficacy: Clinical studies have demonstrated the efficacy of Octreotide in reducing growth hormone levels, controlling tumor growth, and improving symptoms in patients with acromegaly and certain neuroendocrine tumors.
• Potential Adverse Effects: Common side effects of SANDOSTATIN LAR may include injection site reactions, gastrointestinal disturbances, gallstones, and changes in glucose metabolism. Patients should be monitored closely for adverse reactions and managed accordingly.
• Individualized Treatment Approach: The selection of SANDOSTATIN LAR as a treatment option for acromegaly and neuroendocrine tumors should be based on factors such as tumor characteristics, hormone levels, patient’s symptoms, and treatment goals.